Jul 2026· Archives of Toxicology· 2 citations· 34 references
Medicine
TL;DR
This review revisits CB2 as a central regulator of hepatic pathophysiology, integrating mechanistic insights with preclinical and clinical evidence and targeting CB2 signaling presents a promising therapeutic strategy to mitigate steatosis, inflammatory cascades, and fibrotic progression in chronic liver diseases.
An integrated framework that connects gut microbial ecology with host redox signaling is provided, offering novel mechanistic insights and translational perspectives for the prevention and treatment of oxidative liver diseases.
The biological rationale for PPAR modulation in MASLD is delineated, the biological rationale for PPAR modulation in MASLD is critically evaluated, current preclinical and clinical evidence for pan-PPAR agonists is critically evaluated, and emerging strategies for optimizing their development as comprehensive therapeut...
Man Guo, Qi Wu, Chen-Hao Deng et al.· Metabolism: Clinical and Exp...· 0 citations
Objective To clarify the core regulatory role and molecular mechanism of farnesoid X receptor (FXR) in the progression from liver inflammation/fibrosis to hepatocellular carcinoma (HCC), and to provide a theoretical basis for targeted prevention and treatment of liver diseases. Methods A systematic review was performed...
Qiu-Luo Cheng, Guiqun Huang, Xue Han et al.· Biochemistry and Biophysics...· 0 citations
Type 2 diabetes mellitus (T2D) is a major and growing global health burden that is associated with substantial cardiovascular, renal, and metabolic complications and is increasingly recognized as a systemic disorder involving multiple organs, particularly the liver. Metabolic dysfunction-associated steatotic liver dise...
Georgeta Liliana Foia, Ancuta Goriuc, I. Luchian et al.· International Journal of Mol...· 0 citations
Cardiovascular diseases remain the leading cause of morbidity and mortality worldwide, despite significant advances in diagnostics and pharmacotherapy. This persistent burden has shifted attention toward adjunct therapeutic strategies targeting key mechanisms of myocardial and vascular injury, including oxidative stres...
T. Milivojac, Nataša Stojaković, M. Mikov et al.· Frontiers in Pharmacology· 0 citations
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide and a leading cause of advanced liver fibrosis, cirrhosis, and hepatocellular carcinoma. The disease develops through the interaction of multiple interconnected pathophysiological mechanisms, including in...
T. Radosavljević, J. Djuretić, Milica Branković et al.· Antioxidants· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
